Quick update on that timeline. Seems to have been slightly pushed back to mid 2024 and 2025 commercialisation. My bad on that.
Not sure if Megan is just being conservative but I've only come around to listening to the latest webcast in May.
Anyway still seems like a massive opportunity with great Phase 2B success, clear MOA. Phase 3 design sounds great with the two arms and clear goal of optimising patient care by testing the difference between monthly dosing or once every two months.
Interesting pathways forward. Whether alone or in partnership.
Ann: Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting, page-19
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $409.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $728.0K | 1.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144551 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 6300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |